Richardson, P. G., & Raab, M. (2015). Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. The lancet. Haematology, 2(12), . https://doi.org/10.1016/S2352-3026(15)00197-0
Chicago-Zitierstil (17. Ausg.)Richardson, Paul G., und Marc-Steffen Raab. "Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Final Phase 2 Results from the Randomised, Open-label, Phase 1b–2 Dose-escalation Study." The Lancet. Haematology 2, no. 12 (2015). https://doi.org/10.1016/S2352-3026(15)00197-0.
MLA-Zitierstil (9. Ausg.)Richardson, Paul G., und Marc-Steffen Raab. "Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Final Phase 2 Results from the Randomised, Open-label, Phase 1b–2 Dose-escalation Study." The Lancet. Haematology, vol. 2, no. 12, 2015, https://doi.org/10.1016/S2352-3026(15)00197-0.